Geneva, Switzerland and Boston, MA - 31 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder, Tim ADAMS, CFO, and Mario CORSO, Senior Director Investor Relations will attend the Jefferies Healthcare Conference. Management will be presenting on Thursday June 8th at 08:30 a.m. and will be hosting one-on-one meetings at the Grand Hyatt Hotel in New York City.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
CEO Office contact
Delphine Renaud
[email protected]
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/70181aa5-664e-4bd9-a30f-7dcaa32de878


Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 



